GENE ONLINE|News &
Opinion
Blog

Tislelizumab
BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
2022-04-20
EMA Begins Review of BeiGene, Novartis’s PD-1 Antibody for Esophageal and Lung Cancer
2022-04-13
Novartis Licenses BeiGene’s Antibody for a Potential $2.8 Billion After Its Own Drug Disappoints
2021-12-21
FDA Accepts BeiGene’s BLA for Esophageal Cancer Drug
2021-09-14
Chinese Regulator Accepts BeiGene’s Tislelizumab sBLA for Nasopharyngeal Cancer
2021-08-23
Novartis Fortifies Immuno-Oncology Franchise with BeiGene Collaboration
2021-01-15
Biotech Duo Revise Co-development & Commercialization Agreement of Intelligent Drug Delivery System
2020-10-08
LATEST
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference
2025-01-17
ZYN Nicotine Pouches Receive FDA Marketing Authorization
2025-01-17
Virginia’s Insurance Marketplace Extends Open Enrollment Deadline: A Detailed Report
2025-01-16
2025 Starts with a Jolt: Layoffs Hit the Life Sciences Industry Ahead of JPM
2025-01-16
Eli Lilly Steals the Spotlight at JPM 2025 with $2.5 Billion Power Move Acquisition
2025-01-16
Pre-JPM 2025: The Quiet Deals You May Have Missed Before the Big Show
2025-01-16
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top